Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward layoffs and scrap further development of its flagship seizure med. Now, ...

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares are trading higher on Monday after the company entered into a merger agreement to be acquired by Immedica Pharma AB, implying an enterprise value of ...

STOCKHOLM & RADNOR, Pa., December 30, 2024--(BUSINESS WIRE)--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical ...

Marinus Pharmaceutical MRNS entered into a definitive agreement to sell its Rare Pediatric Priority Review Voucher (PRV) to Novo Nordisk NVO. Pursuant to the asset purchase agreement, Novo Nordisk ...

Marinus Pharmaceuticals is implementing a raft of cost-cutting measures in the wake of last month's phase 3 struggles—including jettisoning a fifth of its workforce. Employees at the ...

Marinus Pharmaceuticals is gearing up for a phase 3 study after its epilepsy drug curbed seizures in patients with a rare, genetic disease that causes benign tumors to grow in various parts of the ...

Marinus Pharmaceuticals MRNS is a micro-cap pharmaceutical stock with multiple Wall Street analysts seeing significant upside. Both Oppenheimer and Cantor Fitzgerald recently issued or reiterated ...

The biopharma's slide continues -- for good reason this time. That's because management decided to delay the readout of preliminary results from an important phase 2 program evaluating its drug ...

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented ...

Marinus Pharmaceuticals Inc ( (MRNS)) has released its Q3 earnings. Here is a breakdown of the information Marinus Pharmaceuticals Inc presented to its investors. Marinus Pharmaceuticals, Inc. is a ...